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Acute-on-chronic liver disease 
enhances phenylephrine-induced 
endothelial nitric oxide release in 
rat mesenteric resistance arteries 
through enhanced PKA, PI3K/AKT 
and cGMp signalling pathways
Laura Caracuel1,2, esther sastre1,2, pablo Llévenes1, Isabel prieto2,3, tania Funes2,3, 
Mª Ángeles Aller4, Jaime Arias4, Gloria Balfagón1,2,5 & Javier Blanco-Rivero1,2,5
Acute-on-chronic liver disease is a clinical syndrome characterized by decompensated liver fibrosis, 
portal hypertension and splanchnic hyperdynamic circulation. We aimed to determine whether the 
alpha-1 agonist phenylephrine (Phe) facilitates endothelial nitric oxide (NO) release by mesenteric 
resistance arteries (MRA) in rats subjected to an experimental microsurgical obstructive liver cholestasis 
model (LC). Sham-operated (SO) and LC rats were maintained for eight postoperative weeks. Phe-
induced vasoconstriction (in the presence/absence of the NO synthase –NOS- inhibitor L-NAME) and 
vasodilator response to NO donor DEA-NO were analysed. Phe-induced NO release was determined in 
the presence/absence of either H89 (protein kinase –PK- A inhibitor) or LY 294002 (PI3K inhibitor). PKA 
and PKG activities, alpha-1 adrenoceptor, endothelial NOS (eNOS), PI3K, AKT and soluble guanylate 
cyclase (sGC) subunit expressions, as well as eNOS and AKT phosphorylation, were determined. 
The results show that LC blunted Phe-induced vasoconstriction, and enhanced DEA-NO-induced 
vasodilation. L-NAME increased the Phe-induced contraction largely in LC animals. The Phe-induced NO 
release was greater in MRA from LC animals. Both H89 and LY 294002 reduced NO release in LC. Alpha-1 
adrenoceptor, eNOS, PI3K and AKT expressions were unchanged, but sGC subunit expression, eNOS 
and AKt phosphorylation and the activities of pKA and pKG were higher in MRA from LC animals. In 
summary, these mechanisms may help maintaining splanchnic vasodilation and hypotension observed 
in decompensated LC.
Liver diseases are among the ten most frequent causes of death in the Western world1. In general, these patholo-
gies are clinically characterised by jaundice, discoloured urine, pale stools, pruritus, spleen enlargement, collateral 
vessel development and portal hypertension, causing a high rate of morbidity and mortality in the human clinical 
field1–3. Rat experimental models of hepatic fibrosis resulting from obstructive cholestasis cause an inflammatory 
activation of hepatic stellate cells, which express different, sometimes overlapping, phenotypes during the course 
of the disease; initially they develop a functional contractile phenotype that is responsible for the triggering of 
portal hypertension. They can then transform themselves into fibroblasts, which synthetize and release collagen, 
consequently causing liver fibrosis, a portal blood flow obstruction, and thus enhancing portal hypertension. 
These cells also acquire an immunological function, which is characterised by the release of both cytokines and 
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chemokines, and therefore attracts leukocytes and thus induces an inflammatory response by the neighbouring 
cells through a paracrine mechanism. Hepatic sinusoidal and Kupffer cells may also play relevant proinflamma-
tory roles, by releasing multiple adhesion molecules and inflammatory mediators. This stimulates a hyperplasia of 
the biliary epithelium and induces a biliary proliferation that would also contribute to the development of portal 
hypertension4,5. Simultaneously to this increase in intrahepatic vascular resistance, the splanchnic bed vascular 
resistance begins to decrease, as an adaptive response to the intrahepatic haemodynamic alterations. The experi-
mental models of liver cholestasis have shown decompensation within six weeks of surgery, together with hepatic 
encephalopathy and ascites, leading to acute-on-chronic liver failure. This decompensation can aggravate the 
cardiovascular disturbances, and cause hypotension and decreased effective blood volume, as well as increased 
cardiac output6,7, eventually leading to patient death.
Different mechanisms have been suggested as contributors to mesenteric vasodilation in liver diseases. 
Enhanced levels of vasodilator factors including endothelial nitric oxide (NO) and the cyclooxygenase derivate 
prostaglandin I2 (PGI2), as well as of adenosine, glucagon and atrial natriuretic peptide, have been reported8–10. 
Additionally, the response to vasoconstrictors like alpha adrenoceptor agonist noradrenaline, angiotensin II, 
thromboxane A2 (TXA2) or arginine-vasopressin have also been described as reduced11–13.
NO generation can be triggered by vasoconstriction in some vessels, as a consequence of sympathetic nerve 
discharge14 or by activation through the alpha1-adrenergic receptor agonist, phenylephrine (Phe)15,16. Dora 
et al.15 were the first to show that Phe led to an increase in endothelial cell calcium concentration that trig-
gered NO release and consequently attenuated vasoconstriction. In line with this, stimulation of smooth muscle 
alpha1-adrenergic receptors also leads to endothelial NO synthase (eNOS) phosphorylation in mouse mesenteric 
arteries17 through complex mechanisms that include phosphorylation on ser1177. eNOS phosphorylation can 
be produced as a result of different enzymatic pathways, including AMPK, PKA, CaMKII or PI3K/AKT18–27. The 
PKA and PI3K/AKT signalling pathways are both reported to be enhanced in liver pathologies28–31.
In view of these results, we aimed to determine whether activating alpha-1 adrenoceptors with Phe facilitates 
the release of endothelial NO in MRA from rats subjected to microsurgical liver cholestasis (LC), a model of 
acute-on-chronic liver disease, as well as the possible enzymatic pathways implicated.
Materials and Methods
Animals. Male Wistar rats were obtained and housed in the Animal Facility of the Universidad Autónoma de 
Madrid (Registration number EX-021U). The research conforms to the European Commission Directive 86/609 
CEE Art. 21 (1995) and the Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85–23, revised 1996). This study has been approved by the ethical com-
mittee of the Universidad Autónoma de Madrid.
surgical procedure. Rats (Initial weight: 294.5 ± 2.9 g) were divided into two groups: Sham-operated (SO; 
n = 25), in which the common bile duct was only dissected; and microsurgical liver cholestasis (LC; n = 25), in 
which the extrahepatic biliary tract was microsurgically resected7,32,33. Surgery was performed under aseptic but 
not sterile conditions, using a binocular operatory microscope (Zeiss, OPMI 1-FR). Briefly, rats were anaesthe-
tised with ketamine hydrochloride (100 mg/kg) and xylazine (12 mg/kg) i.m. Bile duct anatomy in the rat has an 
intrahepatic and an extrahepatic portion, similar to humans. However, the difference lies in that rats lack a gall 
bladder. Additionally, rat liver has four lobes, while human liver only has two. Therefore, the extrahepatic portion 
is comprised for four biliary ducts, one draining each lobe, all of which gather to form the common bile duct4,5. 
In the SO group, we identified and dissected the biliary ducts in continuity with the common bile duct up to the 
beginning of its intrapancreatic portion. This extrahepatic bile duct was not resected. In the LC group, the com-
mon bile duct was ligated (silk 4/0) and sectioned close to the beginning of its intrapancreatic portion. The dis-
section and excision of the bile ducts from the four liver lobes of the rat must be done without injuring either the 
portal or, and most importantly, the arterial vascularisation of these lobes. The abdomen was closed in two layers 
by continuous running sutures using an absorbable suture (3/0 polyglycolic acid) and silk (3/0). Buprenorphine 
s.c. (0.05 mg/kg/8 hours) was administered postoperatively for analgesia during the first 24 hours post-surgery.
Rats were housed at a constant room temperature, humidity and 12 h light/dark cycle with free access to tap 
water and standard rat chow. Systolic blood pressure (SBP) was measured using the tail-cuff method7,34,35 8 weeks 
after surgery was performed.
portal vein pressure measurement. Portal vein pressure measurement (PP) was performed under 
anaesthesia (100 mg/kg ketamine hydrochloride, 12 mg/Kg xylazine, i.m.). Splenic pulp pressure, an indirect 
measurement of portal pressure (PP) was measured by inserting a fluid filled 20-gauge needle into the splenic 
parenchyma7,36,37. The needle was joined to a PE-50 tube and then connected to a pressure recorder (PowerLab 
200 ML 201) and a transducer (Sensonor SN-844) with a Chart V 4.0 computer program (ADI Instruments); 
these were calibrated before each experiment. The pressure reading was considered satisfactory when a stable 
recording was produced. Previous studies have demonstrated the excellent correlation between splenic pulp pres-
sure and PP38.
Afterwards, animals were sacrificed by exsanguination by puncture of the infrahepatic inferior vena cava. 
Ascitic liquid was collected, and liver, spleen and the mesenteric arcade were removed and placed in cold Krebs−
Henseleit solution (KHS, in mmol/L: NaCl 115; CaCl2 2.5; KCl 4.6; KH2PO4 1.2; MgSO4∙7H2O 1.2; NaHCO3 25; 
glucose 11.1, Na2EDTA 0.03) at 4 °C.
serum biochemical test. Blood samples were kept at room temperature for 2 hours, and afterwards centri-
fuged (2000 g, 10 min, 4 °C). The supernatant (serum) was collected and kept at −70 °C until use. Serum levels of 
the following hepatobiliary metabolites were determined in an autoanalyzer: total and direct bilirubin (TB and 
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DB); alkaline phosphatase (AP); bile acids (BA); aspartate aminotransferase (AST); alanine aminotransferase 
(ALT); lactate dehydrogenase (LDH); total proteins (TP) and albumin,.
Vessel preparation. For reactivity experiments the third order branch of the mesenteric arcade (diameter, 
in μm: SO: 263.25 ± 4.06, n = 10, LC: 268.04 ± 5.46, n = 10, P > 0.05) was dissected from the mesenteric bed, 
cleaned of connective tissue and cut into segments of approximately 2 mm in length. Two tungsten wires (40 µm 
diameter) were introduced through the lumen of the segments and mounted in a small vessel myograph (Danish 
Myo Technology A/S, Aarhus, Denmark) to measure isometric tension according to the method described by 
Mulvany and Halpern39. After a 30 min equilibration period in oxygenated KHS at 37 °C and pH 7.4, segments 
were stretched to their optimal lumen diameter for active tension development. This was determined based on 
the internal circumference-wall tension ratio of the segments by setting their internal circumference, L0, to 90% of 
what the vessels would have if they were exposed to a passive tension equivalent to that produced by a transmural 
pressure of 100 mmHg39.
experimental protocols. After a 45 minute-equilibration period, each arterial segment was exposed twice 
to KCl (120 mmol/L) to assess its maximum contractility. KCl exposure was maintained for 30 minutes, in order 
to get the maximal contraction produced by this agent. Then, the vessels underwent several washout periods until 
basal tone was recovered. Afterwards, the rings were contracted with a Phe concentration that induced approx-
imately 50% of the KCl contraction, and then acetylcholine (ACh; 1 µmol/L) was added to assess the integrity of 
the endothelium. Some experiments were performed in endothelium-denuded vessels. The endothelium was 
removed before mounting the segments in the myograph by gently rubbing the intimal surface with a human hair. 
The effectiveness of endothelium removal was confirmed by the inability of ACh to relax Phe-contracted arteries.
After 60 minutes, cumulative concentration-response curves for Phe (100 nmol/L-0.1 mmol/L) were per-
formed in arteries from both experimental groups. The effects of endothelium denudation, as well as of the non-
selective NO synthase inhibitor Nω-nitro-L-arginine methyl ester (L-NAME, 100 µmol/L) were investigated on 
concentration-response curves for Phe.
The vasodilation induced by concentration-response curves for ACh (1 nmol/L-10 μmol/L), and NO donor 
diethylamine NONOate (DEA-NO, 0.1 nmol/L-0.1 mmol/L) was analysed in Phe-precontracted MRA from both 
SO and LC rats. The effect of the superoxide dismutase mimetic 4-hydroxi-2,2,6,6-tetramethylpiperidinoxyl 
(Tempol, 0.1 mmol/L) on DEA-NO vasodilator response was also determined. The vasoconstrictor response 
induced by TXA2 receptor agonist U46619 (0.1 nmol/L-5 μmol/L) was examined as well.
All drugs were added 30 min before performing the concentration-response curve, and did not alter the arte-
rial basal tone.
NO release. NO release was determined as previously described34. The second, third and fourth branches of 
MRA from SO and LC rats were equilibrated for 30 min in HEPES buffer (in mmol/L: 119 NaCl, 20 HEPES, 4.6 
KCl, 1 MgSO4.7H2O, 0.15 Na2HPO4.12H2O, 0.4 KH2PO4, 5 NaHCO3, 1.2 CaCl2.2H2O, 5.2 glucose, pH 7.4) at 
37 °C (stabilisation period). Afterwards, arteries were incubated with the fluorescent probe 4,5-diaminofluorescein 
(2 µmol/L) for 45 min, and medium was collected to measure the unspecific DAF fluorescence. Once the organ 
bath was refilled, Phe was added cumulatively (100 nmol/L-0.1 mmol/L) at 2 min intervals. The medium was only 
collected at the end of the concentration-response curve to Phe. The fluorescence of the medium was measured 
at room temperature using a spectrofluorimeter (Fluoroskan Ascent, MTX Labsystems, Finland, FL WINLAB 
Software) with excitation wavelength set at 492 nm and emission wavelength at 515 nm. Some segments were 
preincubated with L-NAME (100 μmol/L), the specific inducible NOS (iNOS) inhibitor 1400 W (1 μmol/L), the 
PKA inhibitor H89 (1 μmol/L) or with the PI3K inhibitor LY294002 (10 μmol/L). Considering the unspecificity 
of DAF fluorescence40,41, the stimulated NO release was calculated by subtracting the L-NAME resistant fluores-
cence from the NO release evoked by Phe. Also, blank measurement samples were collected from the medium 
without mesenteric segments in order to subtract fluorescence background emission. The amount of NO released 
was expressed as arbitrary fluorescence units per milligram of tissue.
pKA and pKG activity assays. The second, third and fourth branches of MRA from SO and LC rats were 
frozen in liquid nitrogen and stored at –70 °C. PKA and PKG activities were respectively determined using a 
PKA kinase activity assay kit (Abcam), and a CycLex® Cyclic GMP dependent protein Kinase Assay Kit (MBL 
International Corporation). The frozen arteries were homogenised in a lysis buffer containing 1 mmol/L sodium 
vanadate, 1% SDS and pH 7.4, 0.01 mol/L Tris-HCl and centrifuged at 12,000 g for 10 min at 4 °C. The supernatant 
was then collected and used for the assay. Assays were performed following the manufacturers’ protocols. Protein 
content was measured using a DC protein assay kit (BioRad). Results were expressed as Optical Density (OD) 
Units/μg protein.
Western blot analysis. Western blot analysis was performed as previously described34. For these exper-
iments, 20 μg protein were loaded in each lane. We used a monoclonal purified mouse anti-eNOS/NOS Type 
III antibody (1:2500; BD Biosciences), a rabbit polyclonal antibody against eNOS phosphorylated in Ser1177 
(P-eNOS, 1:2000; Abcam), a mouse monoclonal antibody against iNOS (1:5000 dilution; Transduction 
Laboratories), a mouse monoclonal anti-soluble guanylate cyclase –alpha1(sGC-α1) subunit antibody (1:500; 
Santa Cruz), a mouse monoclonal anti-soluble guanylate cyclase –beta1 (sGC-β1) subunit antibody (1:500; 
Santa Cruz), a mouse monoclonal anti-alpha 1 adrenergic receptor antibody (1:1000; Abcam), a rabbit poly-
clonal anti-PI 3 Kinase p85 beta antibody (1:2000; Abcam), a rabbit polyclonal anti-pan-AKT antibody (1:500; 
Abcam), a rabbit polyclonal anti-pan-AKT (phospho T308) antibody (P-AKT, 1:500; Abcam), and a monoclonal 
anti-β-actin-peroxidase antibody (1:50000; Sigma-Aldrich). Appropriate positive controls (+C) were used for 
each analysis (see figure legends).
4Scientific RepoRts |          (2019) 9:6993  | https://doi.org/10.1038/s41598-019-43513-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
tXB2 and 6-ketoPGF1α releases. The TXA2 and PGI2 releases were determined by monitoring their sta-
ble metabolites using the commercial kits Thromboxane 2 ELISA Kit and 6-keto Prostaglandin F1α ELISA Kit 
(Cayman Chemical), respectively. For sample collecting, MRA arteries were pre-incubated for 30 min in 2 mL 
of KHS at 37 °C, continuously gassed with a 95% O2–5% CO2 mixture (stabilisation period). This was followed 
by two washout periods of 10 min in a bath of 0.2 mL of KHS after which the medium was collected to meas-
ure basal release. Afterwards, arteries were subjected to a Phe concentration curve (100 nmol/L-0.1 mmol/L) at 
1 min intervals. The medium was only collected at the end of the concentration-response curve to Phe. Basal and 
Phe-induced samples were immediately frozen in liquid nitrogen and conserved at −70 °C until the assays were 
performed. All assays were carried out according to the manufacturer’s instructions. Results were expressed as pg 
prostanoid/mL mg tissue.
Drugs. Phenylephrine hydrochloride, acetylcholine chloride, diethylamine NONOate, diethylammonium salt, 
Nω-nitro-L-arginine methyl ester, H89, LY 294002, sodium vanadate, SDS, Trizma-Base, and 4-hydroxi-2,2,6,
6-tetramethylpiperidinoxyl (Tempol) were purchased from Sigma-Aldrich (Madrid, Spain). U46619 was pur-
chased from Cayman Chemical (Michigan, USA). Stock solutions (10 mmol/L) of drugs were made in distilled 
water, except for Tempol, H89 and LY 294002, which were dissolved in dimethylsulfoxide (DMSO), and adminis-
tered so that the maximum DMSO concentration of the medium was less than 0.001%. These solutions were kept 
at −20 °C and appropriate dilutions were made on the day of the experiment.
statistical analysis. Phe and U46619-contractile responses were expressed as a percentage of the maxi-
mum response produced by KCl. ACh and DEA-NO relaxation responses were expressed as a percentage of 
the previous tone elicited by Phe. All values are expressed as means ± S.E.M. of the number of animals used 
in each experiment. To determine differences in the effect of endothelium removal or L-NAME preincubation 
on the response to Phe, we analyzed the differences between areas under the curve (dAUC), expressed as the 
percentage of increase in that area produced by each procedure. These data, together with Emax and logEC50, 
were obtained after adjusting the concentration-response curves with a non-linear regression (variable slope), 
using Graph Pad Prism 6.0 Software. Statistical analysis compared the curves obtained between experimental 
groups, or the curves obtained in the presence of the different substances with the control curve by means of a 
repeated-measure two-way ANOVA followed by a Bonferroni post-hoc test using Graph Pad Prism 6.0 Software. 
For the dAUC, Emax and logEC50 data, NO and TXB2 release, PKA and PKG activities, and Western blot exper-
iments, an unpaired Student’s t test was used. A P value < 0.05 was considered significant.
Results
Animal evolution. All LC animals showed jaundice and choluria. Paraoesophageal, splenorenal and para-
rectal collateral vessels developed in LC animals (Data not shown). Body weight gain was less in LC animals. Low 
systolic blood pressure, portal hypertension, spleen and liver hypertrophy, and ascitic fluid extravasation were 
also observed in LC animals (Table 1).
Regarding hepatic metabolism, we found an increase in total and direct bilirubin (TB; DB), alkaline phos-
phatase (AP), bile acids (BA), and aspartate aminotransferase (AST) in serum from LC rats. In addition, serum 
lactate dehydrogenase, total protein and albumin concentrations were diminished due to LC (Table 2).
These observations confirm the effectiveness of this surgery in producing an acute-on-chronic liver failure.
Vasoconstrictor response to KCl. To check smooth muscle integrity, and possible differences regarding 
the vascular contractile machinery between the experimental groups, we subjected the MRA segments to a depo-
larising solution of KCl (120 mmol/L). The vasoconstrictor response to KCl was similar in endothelium-intact 
segments from both experimental groups, and endothelium removal did not alter KCl-induced vasoconstriction 
(Table 3).
Acetylcholine-induced vasodilation. Endothelial function is generally studied by analysing the vasodi-
lation induced by the endothelial agonist ACh. The vasodilator response to ACh in Phe-precontracted segments 
was similar in MRA from SO and LC rats (Fig. 1A, Table 4).
Vasoconstrictor response to phenylephrine. Role of alpha-1 adrenoceptors. The concentration- 
dependent contractile response to the alpha-1 agonist Phe was lower in endothelium-intact MRA from LC 
compared to SO rats (Fig. 1B, Table 4).
In order to determine whether these differences were due to alterations in endothelial factor release we 
eliminated the endothelium in several MRA segments from both SO and LC rats. We found that Phe-induced 
BW (g) BWG (g) SBP (mm Hg) PP (mm Hg) LW/BW (%) SW/BW (%) Ascitic liquid (mL)
SO 425.8 ± 5.4 46.7 ± 5.9 110.7 ± 6.8 8.9. ± 3.6 3.14 ± 0.24 0.28 ± 0.04 —
LC 300.1 ± 7.6* 22.6 ± 21* 99.5 ± 4.5* 19.8 ± 5.1* 5.87 ± 1.05* 0.99 ± 0.21* 9.1 ± 1.6
Table 1. Effect of microsurgical liver cholestasis (LC) on body weight (BW), body weight gain (BWG), systolic 
blood pressure (SBP), portal pressure (PP), liver weight-to-body weight ratio (LW/BW), spleen weight-to-body 
weight ratio (SW/BW) and ascitic liquid extravasation in Wistar rats. Results are expressed as means ± S.E.M. 
*P < 0.05 versus SO. n = 20 animals each group.
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TB (mg/dL) DB (mg/dL) AP (U/L) BA (µmol/L) AST (U/L) ALT (U/L) LDH (U/L) TP (g/dL) Alb (g/dL)
SO 0.09 ± 0.01 0.001 ± 0.0002 112.34 ± 8.81 6.78 ± 0.75 146.66 ± 19.96 53.50 ± 7.68 1013.00 ± 128.53 5.97 ± 0.09 3′02 ± 0.04
LC 8.17 ± 0.39* 4.92 ± 0.22* 284.88 ± 15.49* 42.84 ± 3.97* 245.07 ± 17.55* 27.32 ± 2.54* 967.76 ± 86.91 4.28 ± 0.21* 1′62 ± 0.09*
Table 2. Serum levels of total bilirubin (TB); direct bilirubin (DB), alkaline phosphatase (AP), bile acids (BA), 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), total proteins 
(TP) and albumin (Alb) in Sham-Operated (SO) and microsurgical liver cholestasis (LC) rats. Results are 
expressed as means ± S.E.M. *P < 0.05 versus SO. n = 15–20 animals each group.
Contraction (mN)
+E −E
SO 16.72 ± 0.92 13.75 ± 2.15
LC 15.78 ± 0.82 12.85 ± 1.96
Table 3. Effect of exposure to a depolarizing solution of KCl (120 mmol/L) in endothelium-intact (+E) and 
endothelium denuded (−E) mesenteric resistance segments from from sham-operated (SO) and microsurgical 
liver cholestasis (LC) rats. Results are expressed as means ± S.E.M. n = 10 animals each group.
Figure 1. Effect of microsurgical liver cholestasis (LC) on the concentration-dependent relaxation to 
acetylcholine (A) and on the concentration-dependent contraction to phenylephrine (B) in endothelium-
intact rat mesenteric resistance segments. Results (mean ± S.E.M.) were expressed as a percentage of the initial 
contraction elicited by phenylephrine (A) or by KCl (B). n = 10 animals in each experimental group. *P < 0.05 
(Bonferroni post-hoc test).
SO LC
Emax (%) log EC50 Emax (%) log EC50
ACh 89.28 ± 5.9 −7.25 ± 0.21 91.57 ± 6.4 −7.32 ± 0.19
Phe + E 117.8 ± 2.3 −5.79 ± 0.03 112.9 ± 7.2 −5.52 ± 0.09*
Phe –E 123.1 ± 2.1 −6.01 ± 0.03# 124.6 ± 3.3 −5.93 ± 0.04#
Phe + E + L-NAME 118.2 ± 5.4 −6.25 ± 0.13+ 130.8 ± 7.3 −5.83 ± 0.10+
DEA-NO 91.09 ± 2.9 −6.45 ± 0.09 93.78 ± 3.2 −7.28 ± 0.13*
DEA-NO + Tempol 94.41 ± 2.9 −6.57 ± 0.08 91.99 ± 1.9 −7.55 ± 0.07*
U46619 111.2 ± 4.2 −8.01 ± 0.07 103.7 ± 5.0 −7.34 ± 0.08*
Table 4. Emax and log EC50 values of vasomotor responses to acetylcholine (ACh), phenylephrine (Phe), 
DEA-NO and U46619 in mesenteric resistance arteries from sham-operated (SO) and microsurgical liver 
cholestasis (LC) rats. Results are expressed as means + S.E.M. n = 5–10 segments from different animals in each 
group. *P < 0.05 SO vs. LC. #P < 0.05 arteries with endothelium vs. arteries without endothelium. + P < 0.05 
arteries without L-NAME vs. arteries incubated with L-NAME.
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vasoconstriction was greater in both experimental groups after endothelial denudation. (Fig. 2A,B, Table 4). This 
increase was stronger in MRA from LC rats (Fig. 2C).
The last observation led us to hypothesise that LC did not alter the alpha-1 adrenoceptor signalling pathway. 
The fact that the alpha1-adrenoceptor expression was similar in segments from both animal groups confirmed 
this hypothesis (Fig. 2D).
Role of endothelium-derived NO in the vasoconstrictor response to phenylephrine. To assess 
the contribution of endothelium-derived NO to the Phe-induced responses, segments were incubated with the 
NO synthase inhibitor L-NAME. This drug increased the response to Phe in arteries obtained from both experi-
mental groups (Fig. 3A,B, Table 4). The increase was greater in LC than in SO animals (Fig. 3C). Additionally, the 
Emax and log EC50 values showed that the Phe-induced vasoconstriction in the presence of L-NAME was similar 
to the one observed in de-endothelised segments (Table 4).
Since the effect of L-NAME was different in segments from SO and LC rats, we aimed to determine the possi-
ble differences in endothelial NO release, observing that Phe induced NO release in mesenteric arterial segments 
from both groups. The increased NO release was greater in MRA from LC than in SO animals (Fig. 4A). Since 
both the PKA and PI3K/AKT signalling pathways may influence NO release, we used different inhibitors for these 
pathways (H89 and LY294002, respectively), to examine their possible implication in the enhanced NO release in 
MRA from LC rats. We found that both H89 and LY294002 decreased Phe-induced NO release in segments from 
LC rats. Preincubation with the specific iNOS inhibitor 1400 W diminished Phe-induced NO release similarly in 
segments form both SO and LC rats (in percentage of inhibition: SO: 42.8 ± 5.4; LC: 41.7 ± 3.5; P > 0.05; n = 6 
animals each group), while L-NAME abolished Phe-induced NO release in both experimental groups (Fig. 4A). 
Since we found a low DAF fluorescence signal in both experimental groups (in arbitrary fluorescence units: SO: 
0.71 ± 0.22; LC: 0.68 ± 0.21; P < 0.05; n = 6 segments from different animals each group), and considering the 
unspecificity of DAF fluorescence40,41, we subtracted the L-NAME resistant fluorescence from the NO release 
evoked by Phe in all the experimental conditions analysed.
Figure 2. Effect of endothelial denudation on phenylephrine-induced vasoconstriction in mesenteric resistance 
arteries from Sham-Operated (SO, A) and microsurgical liver cholestasis (LC, B) rats. Results (mean ± S.E.M.) 
were expressed as a percentage of the initial contraction elicited by KCl. n = 10 animals per experimental group. 
*P < 0.05 (Bonferroni post-hoc test). (C) Differences of area under the curve (in percentage) in the absence or 
presence of endothelium. (D) Western blot analysis for alpha-1 adrenoceptors in mesenteric resistance arteries 
from SO and LC rats. Each lane is representative of 8 isolated arterial segments from different animals in each 
group. A rat brain homogenate was used as a positive control (+C). Lower panel shows the densitometric 
analysis for the alpha-1 adrenoceptor expression. Results (mean ± S.E.M.) were expressed as the relation 
between the signal obtained for the protein analysed and the signal obtained for β-actin.
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The next step was to determine possible alterations in the expression/activity of the different enzymes impli-
cated in the NO release. We saw that LC did not modify the expression of either iNOS or eNOS, but eNOS phos-
phorylation on Ser 1177 was increased (Fig. 4B). Furthermore, PKA activity was enhanced in MRA from LC rats 
(Fig. 5A), while PI3K expression was similar in segments from both groups, as was AKT expression. However, 
AKT phosphorylation in T308 residue was increased in MRA from LC rats (Fig. 5B). These results confirm an 
implication of both PKA and PI3K/AKT signalling pathways in the activation of eNOS and subsequent endothe-
lial NO release in MRA from LC animals.
Vasodilator response to exogenous DEA-NO. The differential NO role observed in our experimental 
conditions can also be produced by alterations in smooth muscle sensitivity to NO. When analysing the vaso-
dilator response to NO donor DEA-NO we found a greater response in MRA from LC compared to SO animals 
(Fig. 6A, Table 4). Preincubation with the superoxide dismutase mimetic Tempol did not modify DEA-NO vaso-
dilator response in either experimental group (Fig. 6B,C, Table 4), allowing us to rule out a possible influence of 
oxidative stress in these differences.
Since cGMP plays a major role in the vasodilation induced by NO, we consequently analysed whether possible 
differences in the NO-cGMP signalling pathway could be implicated in the enhanced NO-induced vasodilation. 
We found that the expression of the soluble guanylate cyclase (sGC) subunits, sGCα-1 and sGCβ-1, was enhanced 
by LC (Fig. 7A). What is more, LC augmented PKG activity in MRA (Fig. 7B).
Effect of LC on prostanoid participation. Aside from NO, the endothelium releases other vasoactive fac-
tors, such as prostanoids. The main vasoactive prostanoids observed in MRA are TXA2, and PGI2. When analys-
ing the release of these prostanoids by monitoring their stable metabolites, we found that basal prostanoid release 
was similar in both experimental groups (TXB2, in pg/mL mg tissue: SO: 0.001 ± 0.0006; LC: 0.0009 ± 0.0003; 
P > 0.05; 6-keto PGF1α, in pg/mL mg tissue: SO: 0.003 ± 0.0007; LC: 0.002 ± 0.0005; P > 0.05). What is more, 
LC decreased Phe-induced TXB2 release in MRA from LC (Fig. 8A), while it did not modify 6-keto PGF1α 
release (Fig. 8B). These results indicate that the vasoconstrictor prostanoid TXA2 also has an important role in the 
diminished Phe-induced vasoconstriction observed in segments from LC rats. To confirm this, we examined the 
possibility of a possible differential vasoconstrictor effect of TXA2, and found that the vasoconstrictor response to 
TXA2 receptor agonist U46619 was diminished in MRA from LC animals (Fig. 8C, Table 4).
Figure 3. Effect of preincubation with the unspecific NOS inhibitor L-NAME (100 μmol/L) on the 
phenylephrine-induced vasoconstriction in mesenteric resistance arteries from Sham-Operated (SO, A) and 
microsurgical liver cholestasis (LC, B) rats. Results (mean ± S.E.M.) were expressed as a percentage of the initial 
contraction elicited by KCl. n = 10 animals per experimental group. *P < 0.05 (Bonferroni post-hoc test). (C) 
Differences of area under the curve (in percentage) in the absence or presence of L-NAME.
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Discussion
The main results of this study show a decreased vasoconstrictor response to Phe in MRA from LC rats as com-
pared to control arteries. This hyporeactivity is due to NO overproduction caused by 1) augmented PKA and 
PI3K/AKT signalling pathway activity, 2) eNOS activation through phosphorylation at its Ser1177 residue, and 
3) enhancement of the cGMP-signalling pathway activity.
Worldwide, liver pathologies with their associated comorbidities and fatalities are quite prevalent1. Among 
the multiple causes of liver pathology, one of the most characterised is liver cholestasis, which causes a high 
rate of morbidity and mortality in the clinical field1–3. The experimental models of rat hepatic fibrosis through 
obstructive cholestasis initially produce a functional contractile phenotype in hepatic stellate cells, which trans-
form themselves into fibroblasts that release collagen and then proinflammatory cytokines, thus producing an 
obstruction of portal blood flow that leads to portal hypertension4,5. Clinically, the symptoms of these pathologies 
are jaundice, discoloured urine, pale stools, pruritus, enlarged spleen, collateral vessel development and portal 
hypertension, symptoms that may be clinically latent or mild in the first phases. Once the pathology becomes 
decompensated, all the above symptoms become aggravated, producing a clinical picture of acute-on chronic liver 
failure. In the present experimental study, liver fibrosis and hepatomegaly appeared in LC animals. Furthermore, 
there is a decrease in systolic blood pressure, accompanied by portal hypertension, while splenomegaly, collateral 
portosystemic circulation and ascitis were found in LC rats, as we reported earlier7. These modifications concur 
with those of decompensated liver cholestasis, being its evolution faster than the observed in the clinical field, 
hence making this experimental model appropriate for the translational study of the alterations associated with 
this disease.
The vascular disturbances in liver cholestasis have been the object of multiple studies. Mesenteric vasculature 
plays a key role in the development of the hyperdynamic circulatory syndrome of liver pathologies, which can be 
related either to increased response to vasodilator factors and/or a blunted vasoconstrictor response to different 
agonists. The participation of vasoactive factors is known to differ depending on the evolution of the pathology in 
other liver pathologies12,34,36,42. In line with this, we have previously reported increased sympathetic discharge as 
an attempt to counteract the marked splanchnic vasodilation that persists in rat mesenteric artery from decom-
pensated liver cholestasis7. Although alterations in conductance vessels function have been reported in this con-
dition43,44, to the best of our knowledge few studies have analysed the possible alterations of vasoconstrictor 
Figure 4. (A) Phenylephrine-induced NO release in mesenteric resistance arteries from sham-operated (SO) 
and microsurgical liver cholestasis (LC) rats. Influence of preincubation with the specific iNOS inhibitor 
1400 W (1 μmol/L), the unspecific NOS inhibitor L-NAME (100 μmol/L), the PI3K inhibitor LY 294002 
(10 μmol/L) and the PKA inhibitor H89 (1 μmol/L). Data were expressed as arbitrary fluorescence units/
mg tissue. n = 6–16 segments from different animals in each group. (B) Western blot analysis for total and 
phosphorylated endothelial nitric oxide synthase (eNOS) in the Ser 1177 residue (P-eNOS) and inducible 
nitric oxide synthase (iNOS) in mesenteric resistance arteries from SO and LC rats. Each lane is representative 
of 8 isolated arterial segments from different animals in each group. Endothelial cells were used as a positive 
control (+C) for both eNOS and P-eNOS analysis. Activated macrophages were used as a positive control (+C) 
for iNOS analysis. Lower panel shows the densitometric analyses for the expression of each protein. Results 
(mean ± S.E.M.) were expressed as the relation between the signal obtained for the protein analysed and the 
signal obtained for β-actin.
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Figure 5. (A) Effect of microsurgical liver cholestasis (LC) on PKA activity in rat mesenteric resistance 
arteries. Results (means ± S.E.M.) are expressed in optical density (OD) units/μg protein. n = 8 animals each 
group. (B) Western blot analysis for PI3K and total and phosphorylated AKT in the T308 residue (P-AKT) in 
mesenteric resistance arteries from Sham-Operated (SO) and LC rats. Each lane is representative of 8 isolated 
arterial segments from different animals in each group. A rat brain homogenate was used as a positive control 
(+C). Lower panel shows densitometric analyses for the expression of each protein. Results (mean ± S.E.M.) 
were expressed as the relation between the signal obtained for the protein analysed and the signal obtained for 
β-actin.
Figure 6. (A) Effect of microsurgical liver cholestasis (LC) on the concentration-dependent relaxation to 
NO donor DEA–NO in rat mesenteric resistance arteries. Influence of preincubation with the superoxide 
anion scavenger Tempol on mesenteric resistance arteries from Sham-Operated (SO, B) and LC rats. Results 
(mean ± S.E.M.) were expressed as a percentage of the initial contraction elicited by phenylephrine. n = 10 
animals per experimental group. *P < 0.05 (Bonferroni post-hoc test).
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responses in MRA in the acute-on-chronic liver failure associated to decompensated liver cholestasis. It is widely 
known that the decreased MRA vascular tone in liver pathologies has several causes, including a diminished 
vasoconstrictor response to alpha-adrenergic agonists, a pivotal mechanism implicated in the development and 
Figure 7. (A) Western blot analysis for sGC subunits sGCα-1 and sGCβ-1 in mesenteric resistance arteries 
from Sham-Operated (SO) and microsurgical liver cholestasis (LC) rats. Each lane is representative of 8 isolated 
arterial segments from different animals in each group. A rat brain homogenate was used as a positive control 
(+C). Lower panel shows densitometric analyses for the expression of each protein. Results (mean ± S.E.M.) 
were expressed as the relation between the signal obtained for the protein analysed and the signal obtained 
for β-actin. (B) Effect of LC on PKG activity in rat mesenteric resistance arteries. Results (means ± S.E.M.) are 
expressed in optical density (OD) units/μg protein. n = 7 animals per group.
Figure 8. Effect of microsurgical liver cholestasis (LC) on 6-Keto PGF1α release (A), TXB2 release (B). Results 
(mean ± S.E.M.) were expressed as pg prostanoid/mL mg tissue. (C) Vasoconstrictor-response to TXA2 receptor 
agonist U46619 in mesenteric resistance arteries from Sham-Operated (SO) and microsurgical liver cholestasis 
(LC) rats. Results (mean ± S.E.M.) were expressed as a percentage of the initial contraction elicited by KCl. 
n = 5–7 animals each experimental group. *P < 0.05 (Bonferroni post-hoc test).
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maintenance of this hyperdynamic circulation. In line with this, our results showed a blunted vasoconstrictor 
response to alpha-1 agonist Phe in MRA from LC animals, and this decrease was similar to those reported in 
MRA from severely cirrhotic animals by different authors. Some reports agree with our observations45–47, but 
others have found no differences in Phe-induced vasoconstriction48,49. This result would indicate that the mainte-
nance or alteration of Phe-induced vasoconstriction depends on the nature and/or the severity of the pathology.
The Phe blunted vasoconstriction observed in LC animals could be associated with alterations in the contrac-
tile machinery. However, the vasoconstrictor response after exposition to a depolarizing solution of KCl did not 
differ between segments from the two experimental groups, ruling out this possibility. This result agrees with ours 
and other’s previous reports describing the vascular effects of liver pathologies7,34–37,50. However, still other reports 
by other groups have shown a hyporeactivity to KCl in liver diseases51,52. Nevertheless, we must remember that 
the effects of liver pathologies can vary very widely, ranging from a mild liver cirrhosis to the acute-on-chronic 
liver failure described in the present study. The manners in which these pathologies are experimentally induced 
can also have different influences on the respective vascular beds. Thus, the evolution of the pathology, as well as 
the vascular bed used could explain the discrepant results in the different studies.
The vasoconstrictor response to Phe is mediated by the activation of post-synaptic alpha1 adrenoceptors, 
present in both endothelial and smooth muscle cells in this vascular bed53–57. In a previous study we have demon-
strated that LC did not modify smooth muscle cell alpha1 adrenoceptor expression in mesenteric vasculature7. 
We also observed no differences in intact MRA in the present study. Regarding endothelial alpha-1 adrenocep-
tors, and using precontracted rat mesenteric resistance arteries, Filippi et al.54 demonstrated a weak increase 
in endothelial NO release after endothelial alpha 1 adrenoceptor stimulation with low concentrations of Phe. 
However, we and other authors had previously reported that the addition of low Phe concentrations in arteries 
did not alter basal tone58–61, and an initial contraction occurred only when micromolar concentrations of Phe 
were reached. These observations agree with a previous study by Dora et al.61, which reported that the increase 
in intracellular Ca2+ produced in endothelial cells from MRA after stimulation with Phe was minimal in basal 
conditions. Consequently, we consider that, if alterations in endothelial alpha 1 adrenoceptor function existed 
they would be quite minor and no relevant.
Of the numerous substances to be proposed as possible mediators in the decreased splanchnic resistance, 
endothelial factors are thought to play a major role. The vasodilator response to ACh is widely used to determine 
possible alterations in endothelial function. Increases13,34,52,62, decreases63 and no changes64 in ACh-induced vas-
odilation have been reported in mesenteric vasculature from different rat models of liver disease. These inconsist-
encies suggest that the alterations in ACh relaxation depend on the aetiology of the liver pathology, as well as on 
the vascular bed used. In our experimental conditions, we observed similar ACh-induced vasodilator responses 
in MRA from both control and LC rats, suggesting that endothelial function is not affected in our decompensated 
LC model. However, endothelium denudation enhanced the Phe-induced vasoconstriction in MRA from both 
experimental groups, and this increase was greater in LC arteries, suggesting that the endothelium plays a differ-
ent modulatory role of the Phe response in SO and LC rats.
NO is one of the main factors involved in the blunted mesenteric resistance of liver diseases, and, conse-
quently, it is partially responsible for the splanchnic vasodilatation in these patients. Phe stimulation of hamster 
arterioles has been reported to promote an increase in endothelial cell calcium concentration, thus triggering 
NO formation, which consequently attenuates arteriole constriction15. Similar results have been obtained in 
different vascular beds, including mouse and rat mesenteric arteries52,65. However, IP(3), rather than calcium, 
seems to have a role in vascular smooth muscle-to-endothelium communication after stimulation with Phe65. 
Consequently, an eNOS phosphorylation and subsequent increase in NO release occurs17. We observed that pre-
incubation with the unspecific NOS inhibitor L-NAME increased Phe-induced vasoconstriction in MRA from 
both SO and LC rats, and the effect was greater in LC arteries. This result can be associated to the increase in 
endothelial NO release observed in this experimental group, an increase that could be associated to enhanced 
eNOS expression and/or activation. The lack of a difference in eNOS expression between SO and LC animals 
suggests that the enhanced NO release is due to augmented eNOS activity. Therefore, we studied the degree of 
phosphorylation on its Ser1177 residue, which we have previously reported to be responsible for eNOS activation 
in MRA34. This phosphorylation was greater in MRA from LC animals, confirming their higher eNOS activity 
and consequently explaining the increase in NO release observed in segments from LC rats. Aside from eNOS, 
iNOS has also been reported to be increased in both systemic and splanchnic vasculature in liver pathologies34,66. 
We observed that the specific iNOS inhibitor 1400 W diminished Phe-induced NO release to a similar extent in 
both SO and LC MRA segments. Additionally, no differences in iNOS expression were found in our experimental 
conditions. Both results allows us to rule out a different functional role for iNOS in our experimental procedure, 
and point out the possibility that this enhanced iNOS expression could be due to the similar surgical procedures 
induced in both SO and LC rats.
eNOS-Ser 1177 has been reported to be a target of several phosphorylation pathways, including both the PKA 
and PI3K/AKT signalling pathways19–21,25–27, the latter known to be present in liver28–31. Therefore, we aimed to 
determine possible alterations in the components and/or activity of these signalling pathways in LC. We found 
enhanced PKA activity in MRA from LC. Furthermore, the PI3K and AKT expressions were similar in MRA from 
both experimental groups while AKT phosphorylation was increased in arteries from LC rats. Taken together, 
these results suggest that hyperactivation of either the PKA and/or the PI3K/AKT signalling pathways could be 
responsible for an endothelial NO over-release in LC. The fact that the inhibition of either PKA or PI3K dimin-
ished Phe-induced NO release in arteries from LC rats supported us in confirming this hypothesis.
Apart from NO, other powerful vasoactive factors such as prostanoids, endothelial-derived contracting factors 
and endothelium-derived hyperpolarizing factor (EDHF) are released from the endothelium in these arteries67, 
and have a relevant role in regulating the vascular response to different agonists, such as Phe. Surprisingly, we 
observed that Phe-induced vasoconstriction in the presence of L-NAME in MRA from LC was similar to that 
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observed in de-endothelized segments, indicating an exclusive role for NO after stimulation with Phe in these 
animals, and excluding the participation of the other endothelial factors. Similar results were also reported in 
aorta and mesenteric arteries from rats subjected to common bile duct ligation68,69. Multiple interactions have 
been reported between endothelial factors. Relevant results have been described by many authors, showing 
different mechanisms for TXA2 modulation of EDHF depending on the vascular bed analysed70, including an 
important role for prostanoids in situations where NO is enhanced34,36. TXA2 and PGI2 are the main prostanoids 
implicated in the maintenance of vascular tone. Increased TXA2 function has been described in hepatic vascu-
lature in liver diseases71,72, with decreases reported in splanchnic vascular bed34,73, both results agreeing with 
the opposing alterations observed in these vasculatures. In our experimental conditions, we observed that the 
vasoconstrictor response to the TXA2 analogue U46619 was diminished in arteries from LC animals, showing 
that not only the vasoconstrictor response to Phe but also to other agonists is affected by this pathology. To sum 
up, TXA2 release was practically abolished in arteries from LC animals, as previously reported in both human 
and animal models34,73. This result confirms that the participation of this contractile prostanoid, if it exists, is very 
limited in mesenteric vascular bed in LC. On the other hand, we previously reported a major role for PGI2 in the 
development of mesenteric vasodilation in a compensated liver cirrhosis model induced by CCl434. However, the 
PGI2 release was similar in mesenteric vasculature from SO and LC animals, ruling out a possible involvement 
by this vasodilating prostanoid in the development of splanchnic circulation, and suggesting a rearrangement 
in endothelial factor participation depending on the pathology. We and other authors have reached a similar 
conclusion regarding endothelial and nervous factors7,35,36,42. Regarding EDHF, several studies have reported that 
its participation is only pertinent after inhibition of endothelial NO, since otherwise NO would tonically inhibit 
EDHF participation, while increased EDHF activity have been described after endothelial NO inhibition74–76. 
Together, these results indicate very complex interactions between the different endothelial factors and that the 
interactions vary with the vascular tissue as well as the pathology under study.
The reduced EDHF participation previously reported in mesenteric arteries from rats subjected to common 
bile duct ligation could be associated to excessive oxidative stress69. In line with this, we have observed enhanced 
superoxide anion release in MRA from cirrhotic rats induced by CCl434. Elevation in oxidative stress decreases 
NO bioavailability. Consequently, we aimed to analyse the vasodilator response to the NO donor DEA-NO in 
the presence of the superoxide anion scavenger, Tempol; this drug did not modify DEA-NO induced vasodila-
tion in any experimental group, thus ruling out relevant oxidative stress effects in our experimental conditions. 
Nevertheless, DEA-NO induced vasodilation was greater in MRA from LC rats. NO has a very short half-life (20–
30 s) and diffuses freely through the cellular membrane, acting mainly by activating the heterodimeric enzyme 
sGC, consequently enhancing cGMP production, and thus relaxing smooth muscle cells. Since we and other 
authors have observed increased implication of second messenger cGMP on endothelium-dependent and inde-
pendent vasodilation in rat mesenteric vasculature in liver pathologies13,37, we aimed to determine whether the 
cGMP-signalling pathway would be enhanced in MRA from LC. For that purpose, we analysed the expression of 
sGC, and found increased levels of both the sGCα-1 and sGCβ-1 subunits. Similar results have been described 
in different tissues77,78, making us hypothesise that cGMP release may be increased in MRA from LC animals. 
cGMP is a second messenger that can induce, among other effects, the activation of PKG, an enzyme that plays 
a relevant role in vascular smooth muscle relaxation. The activity of this enzyme has been reported to be either 
altered or unaffected in different tissues from animals with liver pathologies79–81. We found greater PKG activity 
in MRA from LC animals, confirming a cGMP involvement in the enhanced vasodilator response to DEA-NO in 
our conditions and, consequently, participation by this second messenger in the hyporreactivity to Phe observed 
in this study.
As mentioned above, SBP was decreased in LC animals, as also described in patients with this pathology. 
Several mechanisms are implicated in the development and maintenance of this hypotension. First, the enhanced 
participation by the NO signalling pathway seems to be relevant in the hypotension observed in LC animals since 
it participates in the splanchnic vasodilation observed in this pathology and, consequently, produces a decrease 
in effective volaemia. In order to counteract this situation, the heart rate increases, raising cardiac output in these 
patients, who also develop collateral blood flow. However, we cannot forget that this pathology courses with a 
decrease in serum albumin, which is implicated in maintaining capillary colloid osmotic pressure. The decreased 
serum albumin results in ascitic liquid accumulation in the abdominal cavity, thus reducing total volaemia and, 
consequently, arterial pressure82. Working together, these mechanisms contribute to the hypotension character-
istic of the pathology.
In summary, the main results of the present study shows a diminished vasoconstrictor response to Phe in 
MRA from decompensated LC rats. This hyporreactivity is a result of NO overproduction produced by aug-
mented activation of both the PKA and the PI3K/AKT signalling pathways. Enhanced cGMP-signalling pathway 
activation could also be implicated in this response. These mechanisms can contribute to the maintenance of 
splanchnic vasodilation and hypotension observed in decompensated LC.
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